Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases

Ramani Ramchandran, Chikh Bengra, Barry Whitney, Kenneth Lanclos, Dorothy Tuan Lo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Acute erythroleukemia (FAB M6) is a rare heterogeneous disease with an increase in red cell precursors and myeloblasts. Three subsets have been described: M6A (myeloblast-rich erythroleukemia); M6B (proerythroblast-rich erythroleukemia); and M6C (myeloblast- and proerythroblast-rich mixed variant). This study was undertaken to define and compare the clinical courses and survival outcomes among M6A, M6B, and M6C variants of erythroleukemia. Sixty-nine cases of M6 leukemia were categorized as consisting of ≥50% erythroid of all nucleated cells and M6A with ≥30% myeloblasts/nonerythroid component; M6B with ≥30% proerythroblasts/erythroid component; and M6C with ≥30% myeloblasts and ≥30% proerythroblasts. The demographics, cell type distribution, and survival (mean ± sd) of these groups were compared. There were 32 M6A, 26 M6B, and 11 M6C patients. No significant difference was seen among the groups in age, sex, or treatment. Compared to M6A, both the M6B (P < 0.0001) and M6C (P < 0.0001) variants showed a statistically significant increase in the percentage of bone marrow erythroid cells, proerythroblasts, and the proerythroblasts/erythroid ratios. Comparing the groups for survival, M6B (3 ± 3.6 months) versus M6A (25 ± 28 months), P < 0.002, and M6C (10 ± 13 months) versus M6A, P < 0.01 had a poorer prognosis. Calculating the proerythroblasts as a component of total bone marrow erythroids provides a complimentary method for delineating the pure red cell erythroleukemia (M6B) and mixed variant (M6C), similar to that for the myeloid/erythroid (M6A) leukemia. Now that it is possible to delineate erythroleukemia subtypes, innovative treatments are indicated to target the malignant erythroid population, which is resistant to myeloid-based therapies. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)5-13
Number of pages9
JournalAmerican Journal of Hematology
Volume65
Issue number1
DOIs
StatePublished - Sep 11 2000

Fingerprint

Granulocyte Precursor Cells
Erythroblasts
Leukemia, Erythroblastic, Acute
Leukemia
Erythroid Cells
Survival
Rare Diseases
Acute erythroleukemia
Bone Marrow Cells
Cell Survival
Therapeutics
Age Groups
Bone Marrow
Demography
Population

Keywords

  • Acute erythroleukemia
  • Proerythroblasts
  • Subclassification

ASJC Scopus subject areas

  • Hematology

Cite this

Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. / Ramchandran, Ramani; Bengra, Chikh; Whitney, Barry; Lanclos, Kenneth; Tuan Lo, Dorothy.

In: American Journal of Hematology, Vol. 65, No. 1, 11.09.2000, p. 5-13.

Research output: Contribution to journalArticle

Ramchandran, Ramani ; Bengra, Chikh ; Whitney, Barry ; Lanclos, Kenneth ; Tuan Lo, Dorothy. / Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. In: American Journal of Hematology. 2000 ; Vol. 65, No. 1. pp. 5-13.
@article{0ae91adbfddd4d6da569be7b5b646191,
title = "Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases",
abstract = "Acute erythroleukemia (FAB M6) is a rare heterogeneous disease with an increase in red cell precursors and myeloblasts. Three subsets have been described: M6A (myeloblast-rich erythroleukemia); M6B (proerythroblast-rich erythroleukemia); and M6C (myeloblast- and proerythroblast-rich mixed variant). This study was undertaken to define and compare the clinical courses and survival outcomes among M6A, M6B, and M6C variants of erythroleukemia. Sixty-nine cases of M6 leukemia were categorized as consisting of ≥50{\%} erythroid of all nucleated cells and M6A with ≥30{\%} myeloblasts/nonerythroid component; M6B with ≥30{\%} proerythroblasts/erythroid component; and M6C with ≥30{\%} myeloblasts and ≥30{\%} proerythroblasts. The demographics, cell type distribution, and survival (mean ± sd) of these groups were compared. There were 32 M6A, 26 M6B, and 11 M6C patients. No significant difference was seen among the groups in age, sex, or treatment. Compared to M6A, both the M6B (P < 0.0001) and M6C (P < 0.0001) variants showed a statistically significant increase in the percentage of bone marrow erythroid cells, proerythroblasts, and the proerythroblasts/erythroid ratios. Comparing the groups for survival, M6B (3 ± 3.6 months) versus M6A (25 ± 28 months), P < 0.002, and M6C (10 ± 13 months) versus M6A, P < 0.01 had a poorer prognosis. Calculating the proerythroblasts as a component of total bone marrow erythroids provides a complimentary method for delineating the pure red cell erythroleukemia (M6B) and mixed variant (M6C), similar to that for the myeloid/erythroid (M6A) leukemia. Now that it is possible to delineate erythroleukemia subtypes, innovative treatments are indicated to target the malignant erythroid population, which is resistant to myeloid-based therapies. (C) 2000 Wiley-Liss, Inc.",
keywords = "Acute erythroleukemia, Proerythroblasts, Subclassification",
author = "Ramani Ramchandran and Chikh Bengra and Barry Whitney and Kenneth Lanclos and {Tuan Lo}, Dorothy",
year = "2000",
month = "9",
day = "11",
doi = "10.1002/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U",
language = "English (US)",
volume = "65",
pages = "5--13",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases

AU - Ramchandran, Ramani

AU - Bengra, Chikh

AU - Whitney, Barry

AU - Lanclos, Kenneth

AU - Tuan Lo, Dorothy

PY - 2000/9/11

Y1 - 2000/9/11

N2 - Acute erythroleukemia (FAB M6) is a rare heterogeneous disease with an increase in red cell precursors and myeloblasts. Three subsets have been described: M6A (myeloblast-rich erythroleukemia); M6B (proerythroblast-rich erythroleukemia); and M6C (myeloblast- and proerythroblast-rich mixed variant). This study was undertaken to define and compare the clinical courses and survival outcomes among M6A, M6B, and M6C variants of erythroleukemia. Sixty-nine cases of M6 leukemia were categorized as consisting of ≥50% erythroid of all nucleated cells and M6A with ≥30% myeloblasts/nonerythroid component; M6B with ≥30% proerythroblasts/erythroid component; and M6C with ≥30% myeloblasts and ≥30% proerythroblasts. The demographics, cell type distribution, and survival (mean ± sd) of these groups were compared. There were 32 M6A, 26 M6B, and 11 M6C patients. No significant difference was seen among the groups in age, sex, or treatment. Compared to M6A, both the M6B (P < 0.0001) and M6C (P < 0.0001) variants showed a statistically significant increase in the percentage of bone marrow erythroid cells, proerythroblasts, and the proerythroblasts/erythroid ratios. Comparing the groups for survival, M6B (3 ± 3.6 months) versus M6A (25 ± 28 months), P < 0.002, and M6C (10 ± 13 months) versus M6A, P < 0.01 had a poorer prognosis. Calculating the proerythroblasts as a component of total bone marrow erythroids provides a complimentary method for delineating the pure red cell erythroleukemia (M6B) and mixed variant (M6C), similar to that for the myeloid/erythroid (M6A) leukemia. Now that it is possible to delineate erythroleukemia subtypes, innovative treatments are indicated to target the malignant erythroid population, which is resistant to myeloid-based therapies. (C) 2000 Wiley-Liss, Inc.

AB - Acute erythroleukemia (FAB M6) is a rare heterogeneous disease with an increase in red cell precursors and myeloblasts. Three subsets have been described: M6A (myeloblast-rich erythroleukemia); M6B (proerythroblast-rich erythroleukemia); and M6C (myeloblast- and proerythroblast-rich mixed variant). This study was undertaken to define and compare the clinical courses and survival outcomes among M6A, M6B, and M6C variants of erythroleukemia. Sixty-nine cases of M6 leukemia were categorized as consisting of ≥50% erythroid of all nucleated cells and M6A with ≥30% myeloblasts/nonerythroid component; M6B with ≥30% proerythroblasts/erythroid component; and M6C with ≥30% myeloblasts and ≥30% proerythroblasts. The demographics, cell type distribution, and survival (mean ± sd) of these groups were compared. There were 32 M6A, 26 M6B, and 11 M6C patients. No significant difference was seen among the groups in age, sex, or treatment. Compared to M6A, both the M6B (P < 0.0001) and M6C (P < 0.0001) variants showed a statistically significant increase in the percentage of bone marrow erythroid cells, proerythroblasts, and the proerythroblasts/erythroid ratios. Comparing the groups for survival, M6B (3 ± 3.6 months) versus M6A (25 ± 28 months), P < 0.002, and M6C (10 ± 13 months) versus M6A, P < 0.01 had a poorer prognosis. Calculating the proerythroblasts as a component of total bone marrow erythroids provides a complimentary method for delineating the pure red cell erythroleukemia (M6B) and mixed variant (M6C), similar to that for the myeloid/erythroid (M6A) leukemia. Now that it is possible to delineate erythroleukemia subtypes, innovative treatments are indicated to target the malignant erythroid population, which is resistant to myeloid-based therapies. (C) 2000 Wiley-Liss, Inc.

KW - Acute erythroleukemia

KW - Proerythroblasts

KW - Subclassification

UR - http://www.scopus.com/inward/record.url?scp=0033847362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033847362&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U

DO - 10.1002/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U

M3 - Article

C2 - 10936857

AN - SCOPUS:0033847362

VL - 65

SP - 5

EP - 13

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -